Lilly reports positive interim results from Heart-2 trial of VERVE-102
Eli Lilly and Company has reported positive interim results from the ongoing Phase Ib Heart-2 clinical trial of VERVE-102, an …
Post
-
-
Caliway secures FDA clearance for CBL-514 clinical trial
Caliway Biopharmaceuticals has received the US Food and Drug Administration (FDA) clearance for its CBL-0302 Investigational New Drug (IND) application, …
-
FDA leadership in flux, but core operations remain stable, former FDA staff say
At a time when there is a significant void at the top of the US Food and Drug Administration (FDA), …
-
Ebola outbreak highlights the rising frequency of infectious disease emergencies
An Ebola outbreak affecting the Democratic Republic of Congo (DRC) and Uganda has been declared a Public Health Emergency of …
-
Q&A: How 3PLs are navigating the latest pharma trends
Pharmaceutical third-party logistics (3PL) providers are moving beyond traditional warehousing into more holistic and strategic commercialization support. At the same …
-
Lilly’s ‘triple G’ agonist triumphs in Phase III trial, but AEs unnerve analysts
Eli Lilly’s ‘triple G’ agonist, retatrutide, has secured another late-stage win in obesity, though analysts question whether the drug will …
-
Biogen and Denali report Phase IIb LUMA trial data for Parkinson’s
Biogen and Denali Therapeutics have reported data from the Phase IIb LUMA study evaluating their investigational leucine-rich repeat kinase 2 …
-
Medtech clinical trials navigate macro trends and regulatory changes
An upcoming conference will investigate the latest trends in the medical devices and medtech clinical trials industry with a focus …
-
First patient dosed in Merck’s Phase III PROCEADE-CRC-03 trial for mCRC
Merck KGaA (Merck) has dosed the first patient in its Phase III PROCEADE-CRC-03 trial, assessing the investigational anti‑carcinoembryonic antigen-related cell …
-
Cruise ship plays a crucial role in the hantavirus outbreak
According to Disease Outbreak News, which was published by the World Health Organization (WHO) on 13 May, there have been …
-
Remepy’s app-drug combo heads for Phase III on mid-stage Parkinson’s win
Remepy is taking its hybrid Parkinson’s therapy, Hybridopa, to Phase III, after the blended app-drug approach offered motor and non-motor …
-
Site success in clinical trials begins with financial certainty
Carolina Carrasco, senior director at IQVIA, explores how fragmented financial workflows can create administrative burden and uncertainty for trial sites. Carolina …
-
Jupiter Endovascular’s pulmonary embolectomy system hits primary endpoints in trial
Jupiter Endovascular has shared positive pivotal trial results for its Vertex pulmonary embolectomy system in treating pulmonary embolism (PE). The 123-patient …
-
Pfizer reports positive Phase II data for PF-07872412 in infants
Pfizer has reported positive results from its Phase II trial evaluating the 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. The …
-
EU region sees increase in multinational trial initiation in Q1 2026
The European Commission (EC), the Heads of Medicines Agencies (HMA), and the European Medicines Agency (EMA) are seeing success in …
